HOOKIPA Pharma Inc

NASDAQ:HOOKUnited States

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.

Contact Information

Headquarters

350 Fifth Avenue, 72Nd Floor, Suite 7240NEW YORK, NY, United States 10118

Phone

---

Fax

302-655-5049

Executives

Non-Executive Independent Chairman of the Board

Julie O'Neill

Chief Executive Officer, Director

Malte Peters

Chief Financial Officer, Executive Vice President, Director

Terry Coelho

Chief Operations Officer

Roman Necina

Chief Scientific Officer

Klaus Orlinger